Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting
Chaitra S. Ujjani, MD, examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.
EP: 1.Navigating Frontline Treatment Options in CLL
EP: 2.Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting
EP: 3.Expert Perspectives on Extended Follow-Up Data from ALPINE
EP: 4.Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL
EP: 5.Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection
EP: 6.Treatment Strategies for Managing BTK Inhibitor Intolerance in CLL
EP: 7.Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL
This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.
Furman discusses data from the SEQUOIA trial, highlighting zanubrutinib’s promising 78% progression-free survival for patients with 17p-deletion chronic lymphocytic leukemia at 48 months. He suggests exploring combinatorial partners like anti-CD20 and BCL-2 inhibitors. The discussion covers predictors of Bruton tyrosine kinase (BTK) inhibitor progression, emphasizing 17p deletion, TP53 mutation, and complex karyotype as significant risk factors.
The 6-year update of ELEVATE-TN reveals intriguing data on adding obinutuzumab to acalabrutinib, showing benefits without a statistically significant improvement in overall survival. Furman emphasizes the importance of identifying patients at risk of progressing on single-agent BTK inhibitors, allowing tailored therapies like obinutuzumab for those who truly need it. This approach optimizes treatment outcomes while minimizing potential risks.
This summary was AI-generated and reviewed by OncLive® editorial staff.
